{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glucagon-like+Peptide+1&page=2",
    "query": {
      "condition": "Glucagon-like Peptide 1",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glucagon-like+Peptide+1&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T02:12:49.360Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04355832",
      "title": "Glucagon-like Peptide-1 in Type 1 Diabetes",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Type1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Glucagon-like peptide-1",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-06-24",
      "completion_date": "2025-09-24",
      "has_results": false,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-07-24T02:12:49.360Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04355832"
    },
    {
      "nct_id": "NCT02423980",
      "title": "G-Pen™ for Hypoglycemia Rescue in T1D Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Glucagon",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xeris Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 7,
      "start_date": "2015-04",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2017-07-07",
      "last_synced_at": "2026-07-24T02:12:49.360Z",
      "location_count": 1,
      "location_summary": "Walnut Creek, California",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02423980"
    },
    {
      "nct_id": "NCT03965130",
      "title": "The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Glucagon",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2019-06-05",
      "completion_date": "2023-07-06",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-07-24T02:12:49.360Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03965130"
    },
    {
      "nct_id": "NCT06272695",
      "title": "Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Volagidemab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "REMD Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "18 Years to 72 Years"
      },
      "enrollment_count": 24,
      "start_date": "2024-02-15",
      "completion_date": "2025-02-01",
      "has_results": false,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-07-24T02:12:49.360Z",
      "location_count": 2,
      "location_summary": "San Deigo, California • Walnut Creek, California",
      "locations": [
        {
          "city": "San Deigo",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06272695"
    },
    {
      "nct_id": "NCT06801015",
      "title": "Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-10-01",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-07-24T02:12:49.360Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06801015"
    },
    {
      "nct_id": "NCT06548490",
      "title": "GLP-1R Agonist Treatment for Opioid Use Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid Use Disorder",
        "Opioid Abuse and Addiction",
        "Narcotic-Related Disorders",
        "Substance-Related Disorders",
        "Chemically-Induced Disorders",
        "Mental Disorder",
        "Opioid"
      ],
      "interventions": [
        {
          "name": "Semaglutide Pen Injector",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 200,
      "start_date": "2025-01-13",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-07-24T02:12:49.360Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • New York, New York • Harrisburg, Pennsylvania",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Harrisburg",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06548490"
    },
    {
      "nct_id": "NCT01552603",
      "title": "Artificial Pancreas Control System in an Inpatient Setting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type I Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Artificial Pancreas Control Software",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Legacy Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 14,
      "start_date": "2012-03",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-07-24T02:12:49.360Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01552603"
    },
    {
      "nct_id": "NCT03508739",
      "title": "Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Pre-diabetic",
        "Hypertension",
        "Elevated Blood Pressure"
      ],
      "interventions": [
        {
          "name": "Sacubitril/Valsartan 200mg (blinded)",
          "type": "DRUG"
        },
        {
          "name": "Valsartan 160mg (blinded)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 25,
      "start_date": "2018-06-01",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-07-24T02:12:49.360Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03508739"
    },
    {
      "nct_id": "NCT02966275",
      "title": "Post Bariatric Closed Loop Glucagon Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Glucagon-only bionic pancreas - glucagon",
          "type": "DEVICE"
        },
        {
          "name": "Glucagon-only bionic pancreas - placebo",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2016-09",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2018-12-13",
      "last_synced_at": "2026-07-24T02:12:49.360Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02966275"
    },
    {
      "nct_id": "NCT06640972",
      "title": "Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triglycerides",
        "Weight Gain Trajectory",
        "Cholesterol, Elevated"
      ],
      "interventions": [
        {
          "name": "RDX-002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Response Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 68,
      "start_date": "2024-09-27",
      "completion_date": "2025-05-13",
      "has_results": true,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-07-24T02:12:49.360Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06640972"
    }
  ]
}